JP2010011868A5 - - Google Patents

Download PDF

Info

Publication number
JP2010011868A5
JP2010011868A5 JP2009238784A JP2009238784A JP2010011868A5 JP 2010011868 A5 JP2010011868 A5 JP 2010011868A5 JP 2009238784 A JP2009238784 A JP 2009238784A JP 2009238784 A JP2009238784 A JP 2009238784A JP 2010011868 A5 JP2010011868 A5 JP 2010011868A5
Authority
JP
Japan
Prior art keywords
seq
bacteria
immune response
neisseria meningitidis
serosubtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009238784A
Other languages
English (en)
Japanese (ja)
Other versions
JP5215275B2 (ja
JP2010011868A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010011868A publication Critical patent/JP2010011868A/ja
Publication of JP2010011868A5 publication Critical patent/JP2010011868A5/ja
Application granted granted Critical
Publication of JP5215275B2 publication Critical patent/JP5215275B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2009238784A 2001-04-17 2009-10-15 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物 Expired - Fee Related JP5215275B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28455401P 2001-04-17 2001-04-17
US60/284,554 2001-04-17
US32683801P 2001-10-03 2001-10-03
US60/326,838 2001-10-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008074708A Division JP2008259503A (ja) 2001-04-17 2008-03-21 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物

Publications (3)

Publication Number Publication Date
JP2010011868A JP2010011868A (ja) 2010-01-21
JP2010011868A5 true JP2010011868A5 (enExample) 2012-01-05
JP5215275B2 JP5215275B2 (ja) 2013-06-19

Family

ID=26962673

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002581466A Withdrawn JP2004529643A (ja) 2001-04-17 2002-04-11 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
JP2008074708A Withdrawn JP2008259503A (ja) 2001-04-17 2008-03-21 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
JP2009238784A Expired - Fee Related JP5215275B2 (ja) 2001-04-17 2009-10-15 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2002581466A Withdrawn JP2004529643A (ja) 2001-04-17 2002-04-11 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
JP2008074708A Withdrawn JP2008259503A (ja) 2001-04-17 2008-03-21 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物

Country Status (10)

Country Link
US (1) US7534444B2 (enExample)
EP (1) EP1379272B1 (enExample)
JP (3) JP2004529643A (enExample)
CN (1) CN1306956C (enExample)
AT (1) ATE455793T1 (enExample)
AU (1) AU2002252638A1 (enExample)
CA (1) CA2439428C (enExample)
DE (1) DE60235155D1 (enExample)
RU (1) RU2322451C2 (enExample)
WO (1) WO2002083711A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
BR0010721A (pt) 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
WO2002020059A2 (en) * 2000-09-01 2002-03-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2005023295A2 (en) * 2003-09-10 2005-03-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
JP2007528217A (ja) * 2004-02-18 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
DE102004023906A1 (de) * 2004-05-13 2005-12-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von chemischen Mikroarrays
WO2007063903A1 (ja) * 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US10527329B2 (en) 2008-04-18 2020-01-07 Denso Corporation Ejector-type refrigeration cycle device
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
EP2823312B1 (en) * 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPH0720878B2 (ja) 1983-11-21 1995-03-08 ザ ウエルカム フアウンデ−シヨン リミテツド 改善された複合体、それらの製造法および該複合体を含有する製剤
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
WO1990006696A2 (en) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
US5128460A (en) * 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
WO1991008772A1 (en) 1989-12-14 1991-06-27 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
RU2068270C1 (ru) * 1993-01-13 1996-10-27 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Антиген менингококков группы в
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
EP0922059B1 (en) 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b
CN100379757C (zh) * 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
DK1185691T3 (da) * 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.

Similar Documents

Publication Publication Date Title
JP2010011868A5 (enExample)
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
EP2886551A3 (en) Meningococcal fhbp polypeptides
JP2012126742A5 (enExample)
FI3501534T3 (fi) Rokotekoostumuksia, jotka käsittävät mutatoitua tekijä h:ta sitovaa proteiinia
WO2011024072A3 (en) Hybrid polypeptides including meningococcal fhbp sequences
JP2011500073A5 (enExample)
JP2010166916A5 (enExample)
JP2011250797A5 (enExample)
JP2012507294A5 (enExample)
JP2008530245A5 (enExample)
NZ612315A (en) Compositions for immunising against staphylococcus aureus
WO2008090223A3 (en) Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
PH12013500453B1 (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
HRP20240847T1 (hr) Novi polisaharid i njegove upotrebe
BR112012007876A2 (pt) "membranas de troca de íons"
JP2011510093A5 (ja) 口腔ケア製品ならびにその使用および製造の方法
JP2010534684A5 (enExample)
JP2013502918A5 (enExample)
JP2010166921A5 (enExample)
WO2011008548A8 (en) Vaccines and compositions against streptococcus pneumoniae
JP2009515831A5 (enExample)
JP2011502165A5 (enExample)
WO2012138570A3 (en) Modulating bacterial mam polypeptides in pathogenic disease
JP2013518052A5 (enExample)